Skip to main content
MedPathMedPath Home
Clinical Trials/NCT03066661
NCT03066661
No Longer Available
Not Applicable

Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions

Hoffmann-La Roche1 site in 1 countryStarted: February 28, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCancers With NTRK, ROS1, or ALK Gene Fusions
DrugsEntrectinib

Overview

Phase
Not Applicable
Status
No Longer Available
Locations
1
OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
  • •Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
  • •Willing and able to provide written, signed informed consent
  • •Medically suitable for treatment with entrectinib (RXDX-101)

Exclusion Criteria

  • •Currently enrolled in an ongoing clinical study with any other investigational agent

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Approved For Marketing
Not Applicable
Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene FusionTumors Harboring NTRK Fusion
NCT03025360Bayer
Completed
Phase 1
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.Locally Advanced Solid TumorsMetastatic Solid Tumors
NCT02097810Hoffmann-La Roche84
No Longer Available
Not Applicable
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene FusionSolid Tumors Harboring NTRK Fusion
NCT03206931Bayer
No Longer Available
Not Applicable
Expanded Access to RXDX-105 for Cancers With RET AlterationsCancers With RET Alterations
NCT03052569Hoffmann-La Roche
Approved For Marketing
Not Applicable
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationNon Small Cell Lung CancerMedullary Thyroid CancerColon CancerBreast CancerPancreatic CancerPapillary Thyroid CancerOther Solid Tumors With Evidence of Activating RET Alteration
NCT03906331Eli Lilly and Company